avatrombopag

enhances megakaryocytopoiesis; structure in first source

Also Known As:

1-(3-chloro-5-((4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)-2-pyridyl)piperidine-4-carboxylic acid; AKR 501; AKR-501; AKR501; Doptelet; E5501 compound; YM 477; YM-477; YM477

Networked: 82 relevant articles (19 outcomes, 29 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - avatrombopag: 82
  - Thiophenes: 257
    - avatrombopag: 82
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - avatrombopag: 82
  - Thiophenes: 257
    - avatrombopag: 82

Experts

1.	Al-Samkari, Hanny: 7 articles (03/2022 - 10/2018)
2.	Kuter, David J: 4 articles (02/2021 - 06/2014)
3.	Allen, Lee F: 4 articles (01/2020 - 01/2018)
4.	Jamieson, Brian D: 3 articles (03/2022 - 11/2018)
5.	Vredenburg, Michael: 3 articles (01/2022 - 01/2020)
6.	Jurczak, Wojciech: 3 articles (01/2021 - 11/2018)
7.	Hassanein, Tarek: 3 articles (01/2020 - 12/2014)
8.	Cuker, Adam: 2 articles (01/2022 - 06/2014)
9.	Markham, Anthony: 2 articles (12/2021 - 11/2021)
10.	Flamm, Steven L: 2 articles (01/2020 - 11/2019)

Related Diseases

1.	Thrombocytopenia (Thrombopenia) 01/01/2019 - "A few studies have shown that avatrombopag is effective against thrombocytopenia. " 01/01/2019 - "Conclusions: This meta-analysis showed that avatrombopag was an effective treatment for thrombocytopenia, but there is sufficient evidence to indicate that adverse events may occur." 01/01/2022 - "Avatrombopag was effective and safe in the management of thrombocytopenia in Chinese patients with CLD. " 04/01/2009 - "These results suggest that AKR-501 is an orally-active TPO receptor agonist that may be useful in the treatment of patients with thrombocytopenia." 01/01/2023 - "The improved effect of post-HSCT thrombocytopenia in adults was found in the administration of avatrombopag which was a new TPO-RA. "
2.	Liver Diseases (Liver Disease) 10/01/2021 - "Avatrombopag was shown to be safe and effective in patients with chronic liver disease. " 12/01/2018 - "The main objectives of this article were to describe the pharmacokinetics (PK) of avatrombopag, to characterize the pharmacokinetic/pharmacodynamic (PK/PD) relationship between plasma avatrombopag concentrations and platelet count, and to identify potential intrinsic and extrinsic factors affecting PK or PK/PD in patients with chronic liver disease (CLD). " 04/01/2022 - "Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia." 11/01/2018 - "This review will evaluate the preclinical pharmacology, pharmacokinetics, clinical studies, safety, indications and drug interactions of avatrombopag, with a focus on its use for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease." 10/06/2023 - "Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure."
3.	Hemorrhage 09/15/2022 - "The incidence of bleeding events was comparable between the avatrombopag and placebo treatment groups in each study. " 09/01/2019 - "Based on the available clinical trials, avatrombopag is superior to placebo in reducing the need for platelet transfusions or rescue procedures for bleeding. " 11/01/2021 - "Similarly, clinical trials in patients with low platelet levels because of CLD showed that giving avatrombopag prior to surgery reduced the need for platelet transfusions or rescue procedures for bleeding. " 01/01/2020 - "Phase 3 data demonstrated the superiority of avatrombopag to placebo in reducing platelet transfusions for bleeding, supporting its recent approval. " 07/01/2023 - "The symptoms of cutaneous hemorrhage diathesis have resolved completely since avatrombopag was introduced and did not reappear despite the decrease in PLT count."
4.	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 08/01/2023 - "Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China." 01/01/2023 - "Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study." 02/17/2022 - "Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension." 12/01/2023 - "Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia." 09/12/2023 - "Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag."
5.	Aplastic Anemia (Anemia, Hypoplastic) 11/14/2022 - "[Avatrombopag combined with standard immunosuppressive therapy in the treatment of severe aplastic anemia with hepatic impairment in six patients]." 11/14/2022 - "[Hematologic responses to avatrombopag switch in TPO-RA refractory aplastic anemia]." 01/01/2023 - "Avatrombopag is effective in patients with chemoradiotherapy-induced aplastic anemia: a single-center, retrospective study." 03/01/2023 - "Efficacy and safety of avatrombopag in aplastic anemia patients with liver disease." 01/01/2022 - "Severe aplastic anemia in a patient with erythropoietic protoporphyria successfully treated by avatrombopag."

Related Drugs and Biologics

1.	Thrombopoietin Receptors
2.	eltrombopag
3.	lusutrombopag
4.	romiplostim
5.	Inosine Triphosphate (ITP)
6.	Thrombopoietin (c-mpl Ligand)
7.	Interleukin-11 (Interleukin 11)
8.	Erythropoietin
9.	Danazol (Azol)
10.	Carnitine (L-Carnitine)

Related Therapies and Procedures

1.	Platelet Transfusion (Blood Platelet Transfusions)
2.	Drug Therapy (Chemotherapy)
3.	Therapeutics
4.	Chemoradiotherapy
5.	Hematopoietic Stem Cell Transplantation